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New drugs are urgently needed for the treatment of tropical
and subtropical parasitic diseases, such as African sleeping
sickness, Chagas’ disease, leishmaniasis and malaria. Enzymes
in polyamine biosynthesis and thiol metabolism, as well as
polyamine transporters, are potential drug targets within these
organisms.Inthepresentreview,thecurrentknowledgeofunique
properties of polyamine metabolism in these parasites is outlined.
These properties include prozyme regulation of AdoMetDC (S-
adenosylmethionine decarboxylase) activity in trypanosomatids,
co-expression of ODC (ornithine decarboxylase) and AdoMetDC
activities in a single protein in plasmodia, and formation of
trypanothione, a unique compound linking polyamine and thiol
metabolism in trypanosomatids. Particularly interesting features
within polyamine metabolism in these parasites are highlighted
for their potential in selective therapeutic strategies.
Key words: α-diﬂuoromethylornithine, Leishmania, malaria,
ornithine decarboxylase (ODC), polyamine, S-adenosylme-
thionine decarboxylase (AdoMetDC), spermidine synthase,
Trypanosoma.
INTRODUCTION
The polyamines (putrescine, spermidine and spermine) occur in
increased concentrations in rapidly proliferating cells including
cancerous cells [1–4]and parasitic organisms [5]. Moreover, their
biosynthetic enzymes also present with increased activities in
thesecells.Thepolyaminesandtheirderivativesmediateavariety
of important functions and are therefore essential to cell growth
and proliferation. Interference with polyamine biosynthesis has
beensuccessfullyappliedtotheclinicaltreatmentofWestAfrican
sleeping sickness caused by Trypanosoma brucei gambiense
and has prompted the notion that polyamine homoeostasis
may also be an important drug target in the other major
protozoan parasites of human importance. These include the
trypanosomatids Trypanosoma cruzi (causing Chagas’ disease)
and Leishmania spp. (causing leishmaniasis), as well as the
apicomplexan Plasmodium spp. causing malaria. These diseases
afﬂict people globally, killing millions and disabling many
more, and impose further threats due to the rapid appearance
and spread of parasite strains (and associated insect vectors)
that are becoming increasingly resistant to current drugs and
insecticides.Eventhoughdistinctdifferencesexistbetweenthem,
the polyamine biosynthetic enzymes have been identiﬁed as
possible drug targets in all of these parasites [5]. In the present
review, recent discoveries in the metabolism of polyamines and
their thiol derivatives are discussed, particularly highlighting the
unique properties of T. brucei, T. cruzi, Leishmania spp. and
Plasmodium spp. Moreover, the exploitation of these properties
in the discovery of novel polyamine-related therapeutics is
considered.
POLYAMINE HOMOEOSTASIS IN THE HUMAN HOST
ODC (ornithine decarboxylase) is a PLP (pyridoxal-5
 -
phosphate)-dependent enzyme that catalyses the conversion
of L-ornithine into putrescine (1,4-diaminobutane), the ﬁrst
step in polyamine biosynthesis [6] (Figure 1). AdoMetDC
(S-adenosylmethionine decarboxylase) catalyses the formation
of dcAdoMet (decarboxylated AdoMet), which donates the
aminopropyl group for the conversion of putrescine into
spermidine, and subsequently of spermidine into spermine [7,8].
The latter reactions are catalysed by SpdS (spermidine synthase)
and SpmS (spermine synthase) respectively [9]. In addition to the
abilityofmammaliancellstosynthesizepolyamines,theycanalso
interconvert polyamines [10]; however, the latter possibility does
not exist in any of the parasites included in the present review.
Human cells are not only capable of synthesizing and
interconverting polyamines, but can also take up polyamines
from their environment [11]. However, physiological ﬂuids
are not a rich source of polyamines and most cells (except
for the mucosal cells of the digestive tract) are therefore
likely to depend on endogenous synthesis. The mechanism of
mammalian polyamine transport remains poorly understood,
and no polyamine transporter has as yet been molecularly
characterized.
The polyamine biosynthetic enzymes of the human host have
been well characterized on a biochemical and structural level.
Human ODC is an obligate homodimer as two shared active sites
are formed at the dimer interface between the N-terminal domain
of one monomeric subunit and the C-terminal domain of the other
[12–14]. The PLP cofactor is bound in a Schiff-base linkage to
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Figure 1 Polyamine biosynthetic pathways and polyamine transporters of trypanosomatid and apicomplexan parasites compared with those of their human
host
The parasites as well as their vectors are depicted. T. brucei is transmitted by tsetse ﬂies and T. cruzi is transmitted by kissing bugs. These trypanosomatids cause sleeping sickness and Chagas’
diseaserespectively.Leishmania spp.aretransmittedbysandﬂies,whereasmalaria-causingPlasmodium parasitesaretransmittedbyAnopheles mosquitoes.Cellmembranetransporters(cylinders)
are sized approximately in proportion to their efﬁciencies. All images are in the public domain with photo images credited to the CDC Public Health Image Library (http://phil.cdc.gov/phil/) and the
human body image to Wikimedia commons (http://commons.wikimedia.org/). Cad, cadaverine; homoT(SH)2, homotrypanothione; On, ornithine; Put, putrescine; ROS, reactive oxygen species; Spd,
spermidine; Spm, spermine.
the Lys
69 residue in the N-terminal domain. In the C-terminal
domainofthesecondsubunit,theCys
360 residueplaysanessential
role in ensuring correct protonation of an intermediate in the
decarboxylation reaction (Figure 2A).
Human AdoMetDC is synthesized as a pro-enzyme, which
undergoesanautocatalyticinternalserinolysisreaction[7,8].This
reactiongeneratesthetwosubunits(α andβ),aswellastheactive
site pyruvoyl group, which is involved in the decarboxylation
process. Human AdoMetDC is a homodimer with two individual
active sites and two putrescine-binding sites (Figure 2B).
Both of the human aminopropyltransferases SpdS and SpmS
exist as dimers of two identical subunits. Neither of the enzymes
requiresacofactorforcatalyticactivity.SpdSandSpmSarehighly
speciﬁc for putrescine and spermidine respectively, as the amine
acceptor for an aminopropyl group from dcAdoMet [15,16]. The
active sites of the two enzymes are similar, but differ in the
sizes of their amine substrate-binding pockets [15,16]. In SpdS
(Figure 2C) [15], as well as in SpmS [16], a ﬂexible gate-keeping
loop keeps the substrate (putrescine or spermidine) in the correct
position for subsequent catalysis and opens to release the product
(Figure 2C).
AFRICAN SLEEPING SICKNESS
African sleeping sickness (African trypanosomiasis) is a fatal
disease caused by infection with two of three subspecies of T.
brucei. The disease is endemic in sub-Saharan Africa in areas
populated by the tsetse ﬂy (genus Glossina), which transmit
the parasites with their bite. It is estimated that 70000–80000
people are infected and that approximately 30000 deaths from
the disease occur annually [17]. The disease progresses from
a haemolymphatic stage to a meningoencephalitic stage. More
than 90% of the reported cases of African sleeping sickness are
caused by T. b. gambiense [18]. This subspecies is responsible
for the more chronic disease, occurring in the central and
western regions, whereas T. b. rhodesiense causes the more
acute disease and is encountered in the eastern and southern
regions of Africa. A third subspecies, T. b. brucei,a n ds e v e r a l
other species (Trypanosoma congolense, Trypanosoma vivax,
Trypanosoma suis and Trypanosoma simiae) cause nagana, a
wasting disease among domestic animals. T. b. brucei is non-
pathogenic to humans, and serves as a model organism for drug
discovery.
Despitethedeathtollandtheheavyburdenofillness,thereisan
acute lack of satisfactory drugs against African sleeping sickness
since all of the drugs in use suffer from serious limitations. These
include a lack of selectivity against the parasite, excessive host
toxicity, emerging drug resistance, requirement for parenteral
administration, limited availability and high cost of treatment.
Polyamine metabolism as a drug target in T. brucei
Putrescine and spermidine are synthesized in T. brucei parasites
by ODC, AdoMetDC and SpdS (Figure 1). However, SpmS
is missing in T. brucei as well as in the other parasites
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Figure 2 Structural descriptions of the polyamine biosynthetic enzymes
(A) Crystal structure of homodimeric human ODC (PDB code 1D7K, grey) superimposed with T. brucei ODC (PDB code 1QU4, monomers shown in orange and yellow). PLP molecules within the
active sites are shown in green. An active site (magniﬁed) of T. brucei ODC containing DFMO–PLP (PDB code 2TOD, pink) and putrescine (PDB code 1F3T, grey) is shown. The Cys360 and Lys69
residues from the DFMO-bound T. brucei enzyme (yellow) and the human apo crystal structure (PDB code 2OO0, orange) are shown. (B) Crystal structure of homodimeric human AdoMetDC (PDB
code 1JEN, yellow and orange for the α-a n dβ-subunits respectively) superimposed with the homology model of monomeric P. falciparum AdoMetDC (pink and grey for the α-a n dβ-subunits
respectively). Putrescine within the charged buried site is shown in green. An active site (magniﬁed) of P. falciparum AdoMetDC containing putrescine from the human structure (PDB code 1I7M,
grey) and the amino acid residues (numbered) that are predicted to mimic putrescine binding in the parasite (yellow) and the human residues that have been shown to interact with putrescine
(orange). (C) Crystal structure of homodimeric human SpdS (PDB code 2O06, yellow) superimposed with the crystal structures of T. cruzi SpdS (PDB code 3BWC, grey) and P. falciparum SpdS
(PDB code 2I7C, pink). MTA and putrescine within the active site are shown in green. The gate-keeping loops of human SpdS and P. falciparum SpdS are shown in blue in the closed positions. The
active site (magniﬁed) of SpdS from P. falciparum containing AdoDATO (grey), MTA (pink) and putrescine (orange) is shown.
dealt with in the present review. T. brucei and other
trypanosomatids are capable of synthesizing a unique conjugate
between GSH and spermidine called trypanothione (N
1,N
8-
bisglutathionylspermidine) (see below). Aspects of polyamine
biosynthesis in T. brucei that are exploitable in possible
therapeutic strategies are discussed below.
Inhibition of ODC in T. brucei
A large number of ODC inhibitors have been developed
and characterized. DFMO (α-diﬂuoromethylornithine or
eﬂornithine), which functions as an enzyme-activated irreversible
inhibitor [19], proved to be very effective against T. b. brucei
[20] and T. b. gambiense [21]. Merrell Dow in fact ﬁled its
New Drug Application for DFMO (called Ornidyl
TM) in 1988,
noting only one indication: T. b. gambiense. Eventually, DFMO
has become the ﬁrst-line drug against late-stage disease, i.e. when
the parasites have invaded the CNS (central nervous system). It
hasbeennicknamed‘theresurrectiondrug’becauseofitsstriking
effects on comatose patients [22].
The effectiveness of DFMO against African sleeping sickness
isprobablyattributabletothefollowingfacts:(i)theparasiteODC
remains irreversibly inhibited due to its slow turnover rate [23],
whereas the inactivated human host ODC is rapidly replaced by
newly synthesized active enzyme; (ii) the extracellular parasite
cannot obtain polyamines from the blood of the host because
of its negligible polyamine uptake capability [24]; (iii) in the
absence of spermidine, the parasites cannot make trypanothione,
and are therefore seriously compromised in their antioxidant
capability (see below); (iv) the polyamine-depleted parasites
exhibit a marked decrease in protein synthesis, in particular
the variant surface glycoprotein coat [25], which is essential
for evasion of the host immune response; (v) AdoMet and
dcAdoMet accumulate dramatically in the parasites and may
cause aberrant methylation [26]; (vi) the polyamine-depleted
parasites differentiate irreversibly into short stumpy forms, which
are incapable of binary ﬁssion and have lost their infectivity for
the vertebrate host [27]; and (vii) since these parasites spend their
entire life-cycle extracellularly they are more directly exposed
to DFMO than are parasites that replicate intracellularly (e.g.
T. cruzi, Leishmania spp. and Plasmodium spp.).
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Crystal structures have been solved for the native T. brucei
ODC, as well as for the enzyme in complex with PLP, DFMO or
putrescine [28,29] (Figure 2A). T. brucei ODC, like human ODC,
is an obligate homodimer with two identical active sites formed
at the dimer interface by interactions between the Cys
360 residue
in the C-terminal domain of one subunit and the Lys
69 residue in
the N-terminal domain of the other subunit [14,30]. The contacts
at the dimer interface are formed primarily by the C-terminal
domains, which interact through six aromatic rings that form
a stacking interaction across the domain boundary [28]. In the
absence of the substrate, the PLP cofactor forms a Schiff base
with the Lys
69 residue in the boundary between the two ODC
subunits. Similarly to the corresponding Cys
360 residue in the
human enzyme [31], the conserved Cys
360 residue in T. brucei
ODC plays an essential role in the formation of a covalent adduct
with DFMO. Within the dimer interface, DFMO forms a Schiff
base with PLP on one of the monomers and a covalent bond to
the Cys
360 residue in the other monomer. The binding of DFMO
inducesa145◦ rotationoftheCys
360 residuetowardtheactivesite,
compared with the native T. brucei ODC structure (Figure 2A)
[28]. This mechanism of action explains the success of DFMO
as a suicide inhibitor of ODC, causing polyamine depletion and
subsequent inhibition of cell growth and proliferation.
Besides its remarkable success against T. brucei, DFMO unfor-
tunatelyhaspoorpharmacokineticcharacteristics.Recentclinical
trials, using DFMO in combination with the trypanocidal agent
nifurtimox, demonstrated that the course of DFMO treatment
could be shortened and simpliﬁed (with infusion every 12 h for
7 days, instead of every 6 h for 14 days) without compromising
the antiparasitic effect of DFMO [32]. This combination therapy
is presently considered suitable for ﬁrst-line use in the treatment
of second-stage West African sleeping sickness.
The active sites of the human and T. brucei ODCs are
very similar, which suggests that rational design of inhibitors
selectively targeting the enzyme of the parasite may prove
challenging. However, the prolonged half-life of T. brucei ODC
compared with that of the human counterpart is obviously a
beneﬁcial characteristic for targeting this protein in the treatment
of African sleeping sickness. Four novel inhibitor classes that
are selective and speciﬁc for T. brucei ODC have recently been
identiﬁed in a high-throughput screen [33]. The most active
compounds, dithioamidines, were shown to be able to inhibit
ODCactivitybybindingtoallostericsitesandtherebycontrolling
enzyme activity.
Inhibition of AdoMetDC in T. brucei
Trypanosomatid genomes are unique in that they contain two
types of AdoMetDC genes: (i) an orthologue to the gene that
encodes a functional AdoMetDC in other species; and (ii) a
paralogous gene, encoding a protein called prozyme, that is cata-
lytically dead but allosterically active [34]. By forming a high-
afﬁnity heterodimer with AdoMetDC, prozyme can up-regulate
the enzyme activity 1200-fold. It has been suggested that the
prozyme has evolved through duplication of the ancestral
AdoMetDC gene and subsequent mutational drift, losing catalytic
activity in the process, but gaining allosteric regulatory function.
Prozyme shares only approximately a 30% amino acid sequence
identity with the catalytically active T. brucei AdoMetDC. In
addition, it is missing several critical residues required for
processing and catalytic activity. In this respect, AdoMetDC
from T. brucei and other trypanosomatids represent a novel
structural subclass of eukaryotic AdoMetDCs, that otherwise
exist as monomers (e.g. plant AdoMetDC) or homodimers (e.g.
mammalian AdoMetDC) [8].
Although not a substrate of AdoMetDC, putrescine was found
to bind and strongly activate the homodimeric mammalian
AdoMetDC, but not the monomeric plant enzyme [8]. There
is positive co-operativity in putrescine and substrate (AdoMet)
binding to the homodimeric form of human AdoMetDC [35].
Interestingly, putrescine was also found to stimulate the activity
of homodimeric T. brucei AdoMetDC, but only had a negligible
effect on the heterodimeric complex with prozyme [34]. It is
conceivable that the allosteric activation of T. brucei AdoMetDC
byprozymeandtheco-operativityseeninthehumanenzymemay
somehow be related [8].
Thediscoveryofprozymeopensupnewprospectsforinhibiting
AdoMetDC in trypanosomatids, either by blocking formation
of the active AdoMetDC–prozyme complex or by stabilizing
the inactive conformation of AdoMetDC. Inhibitors developed
against the heterodimeric active site may block the AdoMetDC
activity more effectively than inhibitors of the homodimeric
active site [34]. It is anticipated that the crystal structures of
the heterodimeric and the homodimeric forms of T. brucei
AdoMetDC will provide valuable information for structure-based
drug design, as well as for understanding of the evolution of the
AdoMetDC gene.
AdoMetDC has been chemically validated as a drug target in T.
brucei. MDL73811 (5
 -{[(Z)-4-amino-2-butenyl]methylamino}-
5
 -deoxyadenosine), a structural analogue of dcAdoMet and an
enzyme-activatedirreversibleinhibitorofAdoMetDC,wasshown
to be at least 100-fold more potent than DFMO against murine T.
b. brucei infections [36]. MDL73811 treatment could even cure
mice infected with a multidrug-resistant strain [36], as well as
clinical isolates of T. b. rhodesiense [37]. In combination, DFMO
and MDL73811 acted synergistically, curing T. b. rhodesiense-
infected mice, thus permitting lower doses to be used [37].
The AdoMet analogue AdoMao [S-(5
 -deoxy-5
 -adenosyl)-
1-aminoxy-4-(methylsulfonio)-2-cyclopentene] inhibits Ado-
MetDC irreversibly [38]. Of several diastereomeric forms
synthesized, trans-1S,4S-AdoMao proved to be the most
promisinginallrespects.ItinhibitedinvitrogrowthofT.b.brucei
bloodformswithanIC50 of0.9 μM,andwasalsoeffectiveagainst
two clinical isolates of T. b. rhodesiense. Interestingly, growth
inhibitionwasconﬁguration-dependent,indicatingthattheunique
trypanosomal AdoMet transporter [39] and/or the trypanosomal
AdoMetDC prefer substrates in the S-conﬁguration. Because of
its minimal effects on human cells, trans-1S,4S-AdoMao may
be considered parasite-speciﬁc. It is possible that the T. brucei
parasitesexhibitafacilitateduptakeofAdoMetanditsanalogues,
whereasonlysmallquantitiesoftheseentermammaliancells[39].
Lead optimization around MDL73811 resulted in an analogue
(Genz-644131) that was 5-fold more potent than MDL73811
against the T. b. brucei AdoMetDC–prozyme complex [40]. This
analogue exhibited a longer half-life than MDL73811 as well as
improved potency and CNS penetration in T. b. brucei-infected
mice. The mechanism by which AdoMetDC inhibitors kill the
parasites is believed to be associated not only with depletion of
spermidine and related thiol derivatives [41], but with the accu-
mulationofAdoMet,whichmaycauseaberrantmethylation[42].
Inhibition of SpdS in T. brucei
Several SpdS inhibitors have been tested against T. brucei
in vitro. These include a nucleoside bisubstrate (transition
state) analogue, namely, AdoDATO (S-adenosyl-1,8-diamino-
3-thiooctane) [43], a relatively large compound (423.5 Da)
that ﬁlls both the dcAdoMet- and putrescine-binding sites
[15]. Two other SpdS inhibitors, CHA (cyclohexylamine) and
dicyclohexylamine, compete with putrescine binding [43], but
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Figure 3 Central role of trypanothione in detoxiﬁcation of hydroperoxides
Hydroperoxides (ROOH) produced by host defence mechanisms are detoxiﬁed in
trypanosomatids to their respective alcohol (ROH) by tryparedoxin-dependent peroxidases
(TXNPx). The reducing equivalents for the reaction are originally derived from NADPH through
a thiol redox chain composed of TryR, T[SH]2/TS2 and tryparedoxin (TXN[SH]2/TXNS2), [SH]2
and S2 refer to the dithiol [reduced] and disulﬁde [oxidized] forms respectively. T[SH]2 is
synthesized by a stepwise conjugation of two molecules of GSH to a spermidine (Spd)
molecule, catalysed by TryS. Insert: chemical structure of T[SH]2 (the spermidine moiety is
highlightedinred).AnanimatedversionofFigure3isavailableathttp://www.BiochemJ.org/bj/
438/0229/bj4380229add.htm.
off-target effects have also been suggested. Administration of
dicyclohexylamine, the most potent of the SpdS inhibitors, to
mice with trypanosomiasis did not increase their survival time.
Nevertheless, RNA interference-mediated silencing of the SpdS
gene in bloodstream form T. brucei led to depletion of polyamine
poolsandthiolderivatives,whichresultedincellgrowthcessation
and ultimately cell death [44,45]. Thus SpdS may be considered
a genetically validated drug target in African trypanosomes,
but chemical validation will have to await the development of
inhibitors that selectively and irreversibly inactivate the enzyme.
Polyamine-dependent redox metabolism as a drug target in T.
brucei
Trypanosomatids have a unique thiol-based redox metabolism,
depending on trypanothione as their principal thiol, in
contrast with their human host, which utilizes GSH [46].
Trypanothione provides reducing equivalents to a variety of
essentialreactionsintheparasitesthroughoxidationofthedithiol
form of trypanothione [T(SH)2 (dihydrotrypanothione/reduced
trypanothionine)] into the disulﬁde form [TS2 (trypanothione
disulﬁde/oxidized trypanothione)]. This is followed by
regeneration of T(SH)2 by TryR (trypanothione reductase), an
NADPH-dependent ﬂavoenzyme (Figure 3). The transfer of
the reducing equivalents from trypanothione is mediated by
tryparedoxins, which are small highly abundant proteins with
oxidoreductase activity. A major function of the trypanosomatid
redox system is to overcome the oxidative stress induced by
the host defence mechanisms. The hydroperoxides produced
by the host are detoxiﬁed to their respective alcohols by a
family of tryparedoxin-dependent peroxidases (Figure 3). For a
comprehensive review of thiol redox homoeostasis see Krauth-
Siegel and Comini [47].
Trypanothione is synthesized from GSH and spermidine by
an ATP-dependent monomeric C–N ligase [TryS (trypanothione
synthetase)], in a two-step reaction with glutathionylspermidine
as an intermediate (Figures 3 and 4). In addition to a TryS
domain, the enzyme contains an amidase domain, which
catalyses the hydrolysis of T(SH)2 into GSH and spermidine
[48]. This bifunctional TSA (TryS-amidase) is a key enzyme
Figure 4 Simpliﬁed model of TSA structure and function
The L. major enzyme has two catalytic domains, a C-terminal TryS domain (orange) and an
N-terminal amidase domain (grey) and catalyses four reactions [96]. The TryS active site is a
triangular-shapedcavitythataccommodateseachofthethreesubstratesATP(brown),GSH(pink)
andspermidine(Spd)(blue).ReactionI:theγ-phosphateofATP,theglycinecarboxylateofGSH
andthe N1-aminegroupofspermidinearepositionedin theortho-centreoftheTrySactive site.
The GSH carboxy group is activated by phosphorylation and the resulting anionic intermediate
issubjectedtoanucleophilicattackbytheN1-amine.Consequently,N1-glutathionylspermidine
(Spd–GSH) is formed, and ADP and Pi are released. Reaction II: new ATP and GSH molecules
occupythevacatedpockets,andSpd–GSHispositionedwithitsN8-aminegroupinthecatalytic
centre and with the peptide chain directed away from the active site. The subsequent reactions
are the same as in Reaction I, producing ADP and Pi, but T[SH]2 instead of Spd–GSH. Reaction
III: in the amidase active site, a thioester is formed with T[SH]2, followed by hydrolytic cleavage
and release of Spd–GSH and GSH. Reaction IV: a thioester is formed with Spd–GSH, followed
by hydrolytic cleavage and release of GSH and Spd.
in trypanothione homoeostasis, catalysing both synthesis
and degradation of T(SH)2 (Figure 4). Experiments with a
tetracycline-dependent conditional double-knockout of TSA in
T. brucei, revealed a marked reduction of T(SH)2 together
with an accumulation of GSH, when the parasites were grown
in vitro without tetracycline [48]. These effects were followed
by inhibition of growth and eventually cell death. In the absence
of tetracycline, the parasites were unable to infect mice, further
validatingTSAasadrugtargetinT.brucei.Iftheamidaseactivity
of TSA was knocked out alone, the inhibitory effects on parasite
growth in vitro and virulence in vivo were less pronounced,
indicating that the TryS function is a better drug target than the
amidase function. TryS has also been chemically validated as a
drug target [49].
Inaddition,TryRhasbeengeneticallyvalidatedasadrugtarget
in T. b. brucei [50]. Trypanosomes lacking TryR are unable to
infect mice, and show increased sensitivity to oxidative stress
[50].Incellcultures,TryRactivityhastobereducedby>90%to
considerablyreducethegrowthrate.Thereforeanydrugdesigned
totargetthisenzymewouldhavetobeexceptionallyeffectivetobe
pharmaceutically relevant. Studies of small-molecule inhibitors
of T. brucei TryR identiﬁed several competitive inhibitors, the
most promising being clomipramine (Ki =3 μM), a CNS-active
drug [51]. However, this compound failed to extend survival
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time in an acute mouse model of African trypanosomiasis. Since
reversible TryR inhibitors may be displaced by accumulation of
TS2, occurring as a consequence of further cellular metabolism
of T(SH)2 (Figure 3), irreversible active-site-directed TryR
inhibitors may be required in a clinical setting. Another major
challenge with druggability of the TryR target is the large size
of its active site, which must accommodate the substrates, TS2
(721 Da) or glutathionylspermidine disulﬁde (867 Da) [51]. It has
been estimated that, for an orally bioavailable drug, the molecular
mass should ideally be under 500 Da [52]. Nevertheless, the
trypanothione pathway and the linked redox pathways (Figure 3)
appear to be essential for T. brucei function, which makes the
enzymes in these pathways suitable drug targets [47,53].
Polyamine transport as a drug target in T. brucei
T. brucei exhibits very low rates of putrescine uptake and no
evidence of any polyamine transporter has been found in the
genome [24]. The parasite is therefore unlikely to circumvent
the effect of DFMO by obtaining putrescine from the host. On the
other hand, T. brucei transfectants expressing LmPOT1, a high-
afﬁnity transporter for both putrescine and spermidine derived
from L. major (see below), were markedly stimulated in their
putrescine uptake [24], indicating that there is a major difference
between these two organisms in their capacity to use extracellular
putrescine.
CHAGAS’ DISEASE
Chagas’ disease (American trypanosomiasis) is a devastating
and potentially life-threatening illness caused by infection with
T. cruzi. It is endemic and widespread in Latin America (19
countries), with 8–11 million chronically infected individuals
mainly residing in rural areas with abject poverty. It is estimated
that 100 million people are at risk and that 14000 deaths occur
annually[17].Recently,thediseasehasspreadtoothercontinents
because of population mobility and failure to cure the chronic
disease. The parasite is most often transmitted to humans by the
infected faeces of ‘kissing bugs’ (mainly by species belonging
to the Triatoma, Rhodnius and Panstrongylus genera). The bugs
hide in cracked walls of adobe houses and come out at night
to suck blood. Reservoirs of parasites are present both in wild
and domestic animals. An individual can also become infected
withT. cruzi throughcontaminatedfood,bloodtransfusion,organ
transplantation, vertical transmission (passed from an infected
mother to her child during pregnancy or birth) or accidental
injection.
Benznidazole and nifurtimox are the only drugs available
againstChagas’disease.Althoughalmost100%effectiveifgiven
soon after infection, these drugs cause adverse reactions in up to
40% of treated patients, and are ineffective against the chronic
form of the disease. Therefore there is a pressing need for new
and better drugs. One problem to consider when designing new
drugs against T. cruzi, is that these parasites circulate in the blood
in high numbers only during the initial acute phase. During the
chronic phase, which is thus far incurable, the parasites reside
intracellularly, mainly in the heart muscle and in the smooth
muscle of the digestive tract.
Polyamine metabolism as a drug target in T. cruzi
The polyamine requirement of T. cruzi is met in a strikingly
different way than in T. brucei. The former trypanosomatid
lacks ODC, the ﬁrst enzyme in polyamine biosynthesis, and is
therefore utterly dependent on uptake of putrescine from the
host (Figure 1). Although T. cruzi does not possess a complete
polyamine biosynthetic pathway, the parasite does express both
AdoMetDC [54,55] and SpdS, implying that once putrescine is
transported into the parasite, it can be converted into spermidine
(and spermine) [56]. Although other trypanosomatids do not
contain spermine, it appears as if T. cruzi SpdS may be somewhat
promiscuous like the Thermotoga maritima SpdS [15] and able
to convert some spermidine into spermine [56].
Inhibition of AdoMetDC in T. cruzi
The auxotrophic nature of T. cruzi for putrescine makes the
polyaminepathwayanespeciallyattractivedrugtarget.Obviously
the lack of ODC in T. cruzi excludes the possibility of using any
of the ODC inhibitors, but the AdoMetDC inhibitor MDL73811
has been shown to decrease the capability of T. cruzi to infect
and multiply in rat heart myoblasts [57]. Since the inhibition of
infectivity was not bypassed by the addition of spermidine or
spermine, it is more likely that the adverse effect of MDL73811
on infectivity is due to the intracellular accumulation of AdoMet
than to polyamine depletion.
As in T. brucei, AdoMetDC is allosterically activated by
prozyme (a catalytically dead homologue), but the T. cruzi
AdoMetDC–prozyme heterodimer also requires putrescine for
activation to reach a similar efﬁciency as that of the fully
activated T. brucei heterodimeric complex [58]. It is interesting
to note that heterodimers formed between prozyme from
T. brucei and AdoMetDC from T. cruzi, and prozyme from T.
cruzi and AdoMetDC from T. brucei, are functional. It has been
suggestedthatthestimulationoftheT. cruzi AdoMetDC–prozyme
heterodimerbyputrescine,mayrepresentaregulatorymechanism
related to the lack of ODC in T. cruzi and its need for putrescine
import from the host cell [58]. Human blood, in which T. brucei
parasites reside, is a poor source of putrescine, whereas the cells
in which T. cruzi parasites reside are rich in putrescine. The fact
that the AdoMetDC–prozyme heterodimer interaction is unique
to the trypanosomatids offers a species-selective mechanism that
canbetargetedindevelopmentofnewtypesofdrugsagainstthese
parasites.
Another group of compounds, MGBG [methylglyoxal-
bis(guanylhydrazone)] and a series of its aromatic derivatives,
are much less potent inhibitors of T. cruzi AdoMetDC than of the
humanenzyme[54].Althoughonesuchderivative(CGP40215A)
h a da nI C 50 of 4.5 nM for T. b. rhodesiense, it was inactive
against T. cruzi amastigotes in murine macrophages in vitro
[59]. Surprisingly, the treatment of T. cruzi AdoMetDC with
another MGBG derivative and substrate analogue (CGP48664A)
at low concentrations and in the absence of putrescine resulted
in an unexpected increase in enzyme activity [60]. These results
suggested that the analogue can bind to the putrescine-binding
site and that, in the presence of putrescine or at high analogue
concentrations, binding is shifted to that of the active site. This
feature is a speciﬁc characteristic of T. cruzi AdoMetDC and
provides important avenues for drug design where activity can be
inhibited by targeting both the putrescine- and substrate-binding
sites.
Inhibition of SpdS in T. cruzi
In addition to AdoMetDC, SpdS may provide an essential
targeting point in T. cruzi polyamine metabolism. However, very
limited information is available regarding the speciﬁc inhibition
oftheT. cruzi SpdS.Thereforestructure-basedinhibitordiscovery
may provide novel inhibitors to target SpdS and this may have
particular application to the inhibition of T. cruzi. The previously
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published crystal structures of T. cruzi SpdS could provide
importantinsightsintoinhibitoridentiﬁcation,astheco-inhibition
of AdoMetDC and SpdS would have severe consequences on the
availability of polyamines for these parasites. To date structures
oftheapoformofSpdSaswellastheproteinwithboundAdoMet
have been solved (Structural Genomics of Pathogenic Protozoa
Consortium, http://www.sgpp.org/description.shtml) [60a]. The
structures are highly similar to that of the mammalian enzyme
but, for both of these structures, the gate-keeping loops were not
deﬁned, which could be due to the absence of bound dcAdoMet.
The relatively large size of the SpdS active site [10–15 Å
(1 Å=0.1 nm), Figure 2C] could again prove problematic for
the design of inhibitors that conform to Lipinski’s rule [52].
Innovative strategies therefore need to be considered in order
to effectively inhibit the enzyme, and at the same time achieve
high selectivity.
Inhibition of polyamine function in T. cruzi with polyamine
analogues
In addition to biosynthesis inhibition through the targeting
of speciﬁc enzyme active sites, polyamine analogues have
been investigated in various organisms to perturb polyamine
homoeostasis. Ample evidence is available to substantiate that
counteraction of polyamine function by these analogues is a
rational approach for anticancer drug development [2]. Although
the mechanisms of action of polyamine analogues differ between
human cells and parasites, some analogues clearly exhibit
antiparasitic effects. Ideally the analogue should (i) use a
polyamine transporter to gain entry into the parasite, thus
competing with the natural polyamines for uptake; (ii) down-
regulate the polyamine biosynthetic enzymes; (iii) reduce the
pools of the natural polyamines; (iv) counteract the natural
polyamines in their infection- and growth-related functions; and
(v) exhibit parasite-selective activity (reviewed in [2,61,62]).
Among the ﬁrst compounds that were synthesized to meet
several of these criteria were the N,N
 -bis(benzyl)polyamine
analogues [63]. Two of these (MDL27695 and MDL27699)
[64] and two N,N
 -bis(ethylthiophene)polyamine analogues
(MDL28302 and MDL29431) [65] were found to inhibit host cell
invasion and intracellular amastigote multiplication of T. cruzi.
These compounds are all analogues of spermine, suggesting that
they may interfere with the intracellular binding and thus the
normal functions of spermine and the other polyamines. In fact
MDL27695 binds to DNA and may compete for spermine- or
spermidine-binding sites on DNA [63].
Polyamine-dependent redox metabolism as a drug target in T. cruzi
T. cruzi, like other trypanosomatids, has a bifunctional TSA
with separate active sites for the synthesis of T(SH)2
and for the amidase reaction, hydrolysing T(SH)2 into
GSH and spermidine (Figure 4) [66,67]. However, T. cruzi
is uniquely capable of converting the alternative polyamine
cadaverine (1,5-diaminopentane) into aminopropylcadave-
rine, bis(aminopropyl)cadaverine and N
1,N
9-bis(glutathionyl)
aminopropylcadaverine (homotrypanothione) [56]. Thus SpdS
andTrySinT. cruzi acceptcadaverineandaminopropylcadaverine
as substrates, in addition to putrescine and spermidine
respectively. A source of cadaverine may be the cadaverine-
containing actinomycetes [68], which are known to reside in the
gut of the Rhodnius vector [69]. The fact that homotrypanothione
disulﬁde is readily reduced by T. cruzi TryR, with similar kinetic
parameters to those of TS2, suggests that it is a physiological
substrate. Another novel thiol, N
1,N
12-bis(glutathionyl)spermine
has also beenidentiﬁedin T. cruzi [66],indicating that the T. cruzi
TryS site in TSA can use spermine as a substrate. Interestingly,
N
1,N
12-bis(glutathionyl)spermine disulﬁde is also a physiological
substrate of TryR [66]. The crystal structure of T. cruzi TryR has
been solved and is nearly identical with the structure of the T. b.
brucei enzyme [51].
Polyamine transport as a drug target in T. cruzi
Asmentionedabove,T. cruzi isadiamine(putrescine/cadaverine)
auxotroph. The rate of putrescine uptake is approximately
40 times higher in T. cruzi than in other trypanosomatids [70],
and exceeds that of spermidine by about as much. Biochemical
characterization of polyamine transport in T. cruzi epimastigotes
showed that the transporter exhibits a high speciﬁcity for
putrescine and cadaverine, but low speciﬁcity for spermidine
and spermine [71]. The parasite can obtain putrescine, but not
cadaverine, from the human host, which lacks this polyamine.
However, as mentioned above, a source of cadaverine may be the
actinomycetes [68] residing in the gut of the vector [69].
The ﬁrst cell-surface polyamine transporter to be molecularly
identiﬁed in eukaryotic cells was a high-afﬁnity putres-
cine/spermidine transporter (LmPOT1) from L. major [24] (see
below). Results from the T. cruzi genome-sequencing project was
screened for amino acid/auxin permeases and 60 PAT (putative
aminoacidtransporter)genesclusteredin12groups(TcPAT1–12)
were identiﬁed [72]. Further investigation of TcPAT12, the most
divergentmemberintermsofaminoacidsequence,revealed55%
amino acid identity with LmPOT1 [73]. Functional expression
of TcPAT12 in Xenopus laevis oocytes indicated that it is a
high-afﬁnity spermidine transporter (Km =14–26 μM). It also
transports putrescine (and L-arginine), but at a 7-fold lower rate
than spermidine [73].
Two orthologues (TcPOT1.1 and TcPOT1.2)o fLmPOT1 were
recently identiﬁed within the T. cruzi genome [74]. Both genes
are heterozygous alleles located on chromosome 11, and their
open reading frames predict polypeptides of 613 and 627 amino
acids with a 95% identity. Hydropathy proﬁles indicate that
both proteins have 12 transmembrane domains with intracellular
N- and C-termini [74]. One of these orthologues, TcPOT1.2,i s
the TcPAT12 gene previously characterized by Carrillo et al.
[73]. In contrast with the earlier ﬁndings, TcPOT1.2 and its
paralogueTcPOT1.1recognizeputrescineandcadaverine(butnot
spermidine or spermine) as ligands [74]. Interestingly, transporter
function and localization is regulated by the polyamine content
of the extracellular milieu [74]. TcPOT1.1, and to some extent
TcPOT1.2, are able to cover the entire cell surface and thus
increase the cell’s putrescine uptake when putrescine becomes
scarce. This suggests that T. cruzi uses a signalling system that
can sense putrescine availability. Collectively, the signalling and
transport systems seem to enable the parasite to overcome its
inability to synthesize polyamines de novo. Given the auxotrophy
for putrescine, these systems are very promising targets
[74].
DAB (1,4-diamino-2-butanone) is a putrescine analogue that
inhibits axenic growth of T. cruzi epimastigotes in a dose-
dependent manner, leading to oxidative stress and subsequent
mitochondrial damage (Table 1) [75]. Co-incubation with
putrescine reversed the inhibitory effects of DAB. Since T. cruzi
is dependent on polyamine uptake for survival, it is postulated
that DAB competes for or inhibits the uptake of putrescine by
the cell-surface putrescine transporter, which consequently leads
to depletion of putrescine, spermidine and trypanothione. It is
therefore conceivable that the oxidative stress observed is due to
lack of trypanothione.
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Table 1 Selected inhibitors of ODC, AdoMetDC, SpdS and polyamine functions that have shown efﬁcacy against parasites
Inhibitory concentrations (IC50,μM) of these drugs against the parasites in vitro are indicated. Values are from references as indicated. The promastigote [(p)] and amastigote [(a)] forms of
Leishmania are indicated.
T. brucei T. cruzi L. donovani P. falciparum
Inhibitor IC50 Reference(s) IC50 Reference IC50 Reference(s) IC50 Reference(s)
ODC inhibitors
DFMO 81 [21] – – ∼30 (p) [84] 1250 [108,114,115]
APA – – – – 42 (p), 5 (a) [86] 1 [108]
AdoMetDC
inhibitors
MDL73811 – – – – 40 (p) [82] 3 [108]
MGBG 32 [139,140] 500 [54] 67 (p) [141] – [120]
CGP48664A 0.49 [59] ∼30 [59] >90 (a) [59] 8.8 [108]
CGP40215A 0.0045 [59] >90 [59] 18 (p), >90 (a) [93] [59] 1.8 [108]
SpdS inhibitors
CHA – – – – – – 19.7 [109]
4-MCHA – – – – – – 1.4 [109]
Dicyclohexylamine –– – – – – >1 000 [109]
Polyamine
analogues/
transport
inhibitors
MDL27695 –– < 1 [64] 18 (p) [142] 3 [127]
DAB – – 1180 [75] 144 (p) [103] – –
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LEISHMANIASIS
Leishmaniasis is a complex of diseases caused by protozoan
parasites of the genus Leishmania [76]. The disease is transmitted
through the bite of infected sand ﬂies of the genera Phlebotomus
and Lutzomyia, which are the most common vectors in the Old
and New World respectively. Leishmaniasis is mainly a zoonotic
disease (with reservoirs in rodents and canines). However, in
Africa and the Indian subcontinent, visceral leishmaniasis caused
by Leishmania donovani is an anthroponotic disease transmitted
from human-to-human by sandﬂies [77].
The main forms of the disease are cutaneous, mucocutaneous
and visceral leishmaniasis, with clinical spectra ranging from
skin ulcers to liver damage and anaemia. The most severe form is
visceral leishmaniasis (also known as kala azar or black fever), in
which the parasites cause hepatosplenomegaly, fever, weight loss
andanaemia[76].Visceralleishmaniasisislethalunlesspromptly
diagnosed and treated. Leishmaniasis is considered endemic in
88 countries with 350 million people at risk [17]. The number
of people infected is estimated to be more than 12 million with
1–2 million new cases of the cutaneous form and 0.5 million new
cases of the visceral form occurring each year. It is estimated that
visceral leishmaniasis causes more than 50000 deaths worldwide
annually.
There are approximately 20 species of Leishmania that infect
humans. Visceral leishmaniasis is mainly caused by three species
of the L. donovani complex (L. donovani, Leishmania infantum
and Leishmania chagasi) and is endemic in approximately 70
countries, although the majority of new cases are conﬁned to
only relatively few countries (India, Bangladesh, Nepal, Brazil,
Kenya, Sudan and Ethiopia) [76]. Leishmania parasites occur in
two different forms, extracellular promastigotes (infectious form)
in the sandﬂy vector, and intracellular amastigotes (replicative
form)withinthephagolysosomesofthehumanhostmacrophages.
Current drug treatments of visceral leishmaniasis suffer from
various drawbacks such as host toxicity, high cost, difﬁculty
to administer and drug-resistance development. Pentavalent
antimonials have been the ﬁrst-line drugs in the treatment of
visceral leishmaniasis for more than 70 years, except in India due
totheextensivedevelopmentofresistance[78–80].Theantifungal
drug amphotericin B has become the second-line treatment of
visceral leishmaniasis, in spite of its severe and potentially lethal
side effects [79,80]. Lipid formulations of amphotericin B with
reduced toxicity have been developed and are now the choice
of treatment for visceral leishmaniasis in developed countries
[79,80]. However, due to high cost, this treatment is not an
option in most of the endemic countries. There are drugs such
as miltefosine and paromomycin in the pipeline with promising
therapeutic effects [80]. Unfortunately, they also suffer from
limitations such as high cost, toxicity, difﬁcult administration
route, long treatment schedule as well as the generation of drug
resistance.
Polyamine metabolism as a drug target in Leishmania spp.
Similarly to T. brucei, Leishmania parasites are able to synthesize
putrescine and spermidine since ODC, AdoMetDC and SpdS
activities are present in the parasite (Figure 1) and trypanothione
is synthesized for redox control.
Systematic experiments by Ullman and colleagues [81–83]
genetically validated the polyamine biosynthetic enzymes in
L. donovani as drug targets. Knockout strains of L. donovani
promastigotes, deﬁcient in ODC, AdoMetDC or SpdS, were all
demonstrated to be auxotrophic for polyamines. The ODC-null
mutants were dependent on either putrescine or spermidine for
their growth in vitro [83], whereas the AdoMetDC- and SpdS-
null mutants were shown to be auxotrophic for spermidine only
[81,82]. Taken together, these results indicate that spermidine,
not putrescine (unless converted into spermidine), is the essential
polyamine for growth of L. donovani promastigotes.
Inhibition of ODC in Leishmania
The potential of polyamine biosynthesis as a drug target in
Leishmania was indicated by the ﬁndings that DFMO effectively
inhibited the growth of L. donovani and Leishmania infantum
promastigotes in culture [84,85]. In addition, APA (1-amino-
oxy-3-aminopropane), a putrescine analogue that inhibits ODC
in the nanomolar range, also reduced growth of L. donovani
promastigotes (and amastigotes) (Table 1) [86,87]. The growth-
inhibitory effect of APA was completely reversed by the
addition of putrescine or spermidine. Interestingly, parasites
overexpressing ODC showed an increased resistance to the
antimonial drug Pentostam, concomitantly with resistance to
APA,indicatingaroleforODCinthedevelopmentofLeishmania
drug resistance (see below) [86].
Although in vivo treatment with DFMO suppressed the number
of parasites in the liver and spleen of mice and hamsters infected
with L. infantum and L. donovani, the effect was limited. These
results suggested at the time that ODC, and possibly the other
enzymes in the polyamine biosynthetic pathway, was not a
useful drug target for treatment of visceral leishmaniasis [88,89].
Since the parasites live and replicate within the macrophages of
the human host, it seemed conceivable that they might escape
polyamine depletion by obtaining polyamines from the host cell
[90].
To determine whether ODC deﬁciency also affects the growth
of the intracellular amastigote form, Ullman and colleagues [91]
investigated the capacity of ODC-knockout strains of virulent L.
donovani to infect mice. The number of parasites in the liver
and spleen of mice infected with the ODC-null mutants were
found to be 6–3 orders of magnitude lower respectively than the
number found in mice infected with the wild-type L. donovani.
The infectivity was restored by episomal complementation of the
ODC knockouts with an ODC expression plasmid, demonstrating
the importance of ODC for growth and survival of L. donovani
amastigotes in the mammalian host [91]. Recently, it was also
shownthatprovisionoforalputrescinecouldrestorethevirulence
of the ODC-deﬁcient parasites [92]. Thus despite earlier contrary
indications, targeting ODC and the other polyamine biosynthetic
enzymes of L. donovani could be a viable approach for treatment
ofvisceralleishmaniasis.Unfortunately,structuralinformationof
any of the leishmanial polyamine biosynthetic enzymes is not
currently available.
Inhibition of AdoMetDC in Leishmania
Potent inhibitors of AdoMetDC, such as CGP40215A and
MDL73811, have been shown to inhibit growth of L. donovani
promastigotes (Table 1) [82,93]. The effects of the enzyme
inhibitors could be reversed by supplementation of putrescine
or spermidine to the growth medium. In addition, it was
demonstrated that overexpression of AdoMetDC in L. donovani
promastigotes increased their resistance to the growth-inhibitory
effect of MDL73811 [82]. However, no effect on the growth of L.
donovani amastigotes in mouse macrophages was observed using
CGP40215A at concentrations up to 90 μM (Table 1) [59].
Genomic analysis of the trypanosomatid AdoMetDC family
indicates that Leishmania spp. also express prozyme [34],
although a functional role for prozyme as an activator of
AdoMetDC has yet to be demonstrated for this parasite [34,58].
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Inhibition of SpdS in Leishmania
Very limited information is available regarding effects of SpdS
inhibitors on Leishmania growth and survival. The only
SpdS inhibitor tested is n-butylamine, which is as potent
as the methylated CHA derivative 4MCHA (trans-4-
methylcyclohexylamine), against the mammalian enzyme [94].
When the effect of n-butylamine was tested against L. donovani
strains overproducing ODC, AdoMetDC or SpdS, it was shown
that not only the SpdS overproducer exhibited resistance to n-
butylamine, but also the ODC overproducer [95]. This may
suggest that n-butylamine is not a speciﬁc inhibitor of SpdS, but
may also act on ODC. A more probable explanation is that the
increased levels of putrescine found in the ODC overproducers
make these cells resistant to the inhibitor, which competes with
putrescine for the same binding site of SpdS. This suggestion
is also supported by the ﬁnding that putrescine supplementation
protected wild-type parasites from n-butylamine toxicity [95].
Inhibition of polyamine function in Leishmania with polyamine
analogues
The N,N
 -bis(benzyl)polyamine analogue MDL27695, was
shown to have potent antileishmanial activity, eliminating 77–
100% of L. donovani amastigotes from mouse macrophages at
a1μM concentration [63]. In mice and hamsters, the parasite
burdenwaseffectivelysuppressedbyMDL27695,andinhamsters
this analogue was equally effective against antimony-resistant
L.donovani.ThemechanismofactionofMDL27695wasthought
to involve interference with DNA and RNA synthesis [63].
Several novel types of polyamine analogues, synthesized by
Cellgate, have been shown to inhibit L. donovani growth in vitro
[95]. The oligoamines CGC-11211 and CGC-11226, and the
macrocyclic polyamine analogue CGC-11235, all exhibited IC50
values of less than 1 μM. By screening various antileishmanial
compounds against L. donovani strains overproducing ODC,
AdoMetDC or SpdS, it was possible to identify those compounds
that exert their effect predominantly by interfering with the
polyamine biosynthetic enzymes [95].
Polyamine-dependent redox metabolism as a drug target
in Leishmania
Structural analysis of L. major TSA revealed two catalytic do-
mains: a C-terminal synthetase domain that generates T(SH)2 and
an N-terminal amidase domain that can hydrolyse T(SH)2 [96].
The C-terminal active site of TryS is a triangular-shaped cavity
that accommodates each of the three substrates (ATP, GSH and
spermidine). The N-terminal amidase active site catalyses the
cleavage of T(SH)2 and glutathionylspermidine, releasing GSH
andspermidine.ThefourreactionscatalysedbyTSAareshownin
Figure4.TheTrySandamidaseactivitiesofthisbifunctionalTSA
obviously must be balanced to achieve the optimal concentrations
of GSH, spermidine, glutathionylspermidine and T(SH)2.B y
restricting access to the amidase active site, the C-terminus may
provide a mechanism by which the levels of these metabolites
can be controlled [96]. This indicates an additional target for
interference with polyamine and related metabolic processes in
this parasite.
The use of pentavalent antimonials as ﬁrst-line drugs in
the treatment of visceral leishmaniasis is threatened by rapid
development of drug resistance. The mechanism by which
Leishmania spp. develop resistance to antimonials has not yet
been fully clariﬁed [97]. It is generally believed that pentavalent
antimonialshavetobereducedtothetrivalentformSb(III)before
being biologically active. The mechanism(s) by which this occurs
is still unknown. However, treatment of L. donovani with Sb(III)
causesarapiddepletionofintracellularT(SH)2 andGSHaswellas
inhibitionofTryR,resultinginaconcomitantaccumulationofthe
disulﬁde forms. This imbalance in thiol homoeostasis is believed
to be lethal to the parasite. Experimentally selected antimonial-
resistant strains of Leishmania spp. often show increased levels
of T(SH)2 and GSH. These are caused by overexpression of γ-
glutamylcysteine synthase and ODC, the rate-limiting enzymes
in the biosynthesis of the two precursors to trypanothione,
GSH and putrescine [98,99]. It is conceivable that increased
synthesis of these thiols renders the cells more resistant to the
perturbing effects of Sb(III) on thiol homoeostasis. Over-
expression of ODC has been found in antimony-resistant ﬁeld
isolatesofL.donovani[86].Antimony-resistantﬁeldisolateshave
also been shown to exhibit elevated levels of tryparedoxin and
tryparedoxin peroxidase, which are involved in hydroperoxide
detoxiﬁcation (Figure 3), strongly indicating that ampliﬁed
antioxidative defences play a major role in clinical resistance
to antimonials [100]. Interestingly, tryparedoxin peroxidase has
been genetically validated as a drug target in T. b. brucei [53].
Polyamine transport as a drug target in Leishmania
Leishmania promastigotes as well as amastigotes are able to take
up polyamines from their environment [101,102]. In Leishmania
spp., the polyamine transport systems are often stage-speciﬁc,
with different polyamine transport systems for the promastigote
and amastigote stages [102]. In promastigotes of L. donovani
and Leishmania mexicana and in amastigotes of L. mexicana,
polyamine transport was found to be temperature- and pH-
dependent [102]. It was also saturable and independent of the
Na
+ concentration, but dependent on the protonmotive force.
Results from kinetic analyses of polyamine transport indicate
the existence of separate transport systems for putrescine and
spermidine in Leishmania. Putrescine transport in L. infantum
promastigotes has been shown to occur via a speciﬁc energy-
dependent and saturable carrier [85].
The cloning of the gene LmPOT1 encoding a high-afﬁnity
putrescine/spermidine transporter from L. major by Hasne
and Ullman [24] was the ﬁrst molecular identiﬁcation of a
eukaryotic cell-surface polyamine transporter. Sequence analysis
predicted a protein of 803 amino acids with 9–12 transmembrane
domains and also indicated that LmPOT1 belongs to the APC
(amino acid/polyamine/organocation) superfamily of membrane
transporters [24]. Expression of LmPOT1 in X. laevis oocytes
induced high-afﬁnity saturable transport of both putrescine and
spermidine. However, when expressed in T. brucei (which
normally transport polyamines poorly) LmPOT1 appeared to
mainly transport putrescine with a Km value similar to that
obtained in the Xenopus oocytes. Immunocytochemical analysis
revealed a high expression of LmPOT1, which was localized to
the cell surface and ﬂagellum of L. major promastigotes [24].
DAB has been shown to be active against L. major
promastigotes by targeting ODC as well as putrescine uptake
into these parasites (Table 1). Similarly to the effect of DFMO
treatment in other organisms, pretreatment of the parasites with
DAB results in an increased uptake of putrescine [103].
MALARIA
Malaria is recognised by the WHO (World Health Organization)
as one of the three most important infectious killers in the world,
with around 350–500 million clinical malaria episodes occurring
annually [104,105]. More than 80% of malaria-associated deaths
occurinAfricasouthoftheSahara.InendemicAfricancountries,
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malaria accounts for 25–35% of all outpatient visits, half of
all hospitalizations and 35% of all hospital deaths. In some
African countries, this disease constitutes 40% of the public
health expenditures. Malaria is also prevalent in many other
subtropicalandtropicalcountries,e.g.inSoutheastAsiaandLatin
America. This disease therefore rates as one of the major health,
socioeconomic and developmental challenges facing many of the
world’s poorest countries.
Malariaiscausedinhumansbyfourmajorspeciesofplasmodia
thataretransferredbythebiteofablood-feedingfemalemosquito
of the Anopheles genus. Plasmodium vivax, Plasmodium ovale
and Plasmodium malariae are less virulent than Plasmodium
falciparum, which causes the most lethal form of this disease.
The recent discovery of the zoonotic transfer of Plasmodium
knowlesi (simian malaria) to humans indicates the evolving
nature of the plasmodia and highlights our need for tight control
of the spread of these parasites to humans [106]. Malaria
parasites mature intracellularly in hepatocytes before infecting
erythrocytes to commence the asexual life cycle. Treatment of
severe malaria is negated by the alarming increase in resistance
of the malaria parasite to all known antimalarials. Traditionally,
malaria prophylaxis relied on antifolates (e.g. pyrimethamine and
sulfadoxine) and chloroquine or its derivatives (e.g. meﬂoquine).
Current treatment regimes advocated by the WHO include
new antimalarials such as artemisinin in combination with
conventional drugs to prolong the useful lifetime of the limited
antimalarialdispensary.Ideallyanantimalarialshouldbeselective
and essentially non-toxic to the human host. It should also have
good oral bioavailability and be curative in a few days to limit the
development of resistance.
Polyamine metabolism as a drug target in P. falciparum
The polyamines are present as major metabolites within
the parasite and, with a total concentration of 10 mM, the
polyamines make up 14% of the P. falciparum metabolome
[107]. P. falciparum-infected erythrocytes contain high levels
of putrescine and spermidine, but only low levels of spermine
(Figure 1) [108]. Like in T. cruzi, spermine is synthesized by a
somewhat promiscuous P. falciparum SpdS, which cannot only
use putrescine, but also spermidine as a substrate (Figure 1)
[109]. There is no evidence of trypanothione synthesis in these
apicomplexan parasites.
Inhibition of the bifunctional AdoMetDC/ODC of P. falciparum
Possibly the most distinctive feature of polyamine biosynthesis
in plasmodia is that a single open reading frame encodes
both ODC and AdoMetDC in a unique bifunctional protein of
∼330 kDa molecular mass (AdoMetDC/ODC) (Figure 5) [110].
The advantage of this bifunctional AdoMetDC/ODC protein
probably is not a metabolic channelling of substrates to optimize
downstream synthesis, because AdoMetDC and ODC do not
catalyse consecutive reactions in the polyamine biosynthetic
pathway. Instead, the bifunctionality may be important for
the regulation of polyamine pools in the parasite [111]. In
contrastwith theirsingle-enzymeorthologuesinotherorganisms,
ODC activity is strongly feedback-inhibited by putrescine, and
AdoMetDC activity is not stimulated by putrescine in the
bifunctional enzyme [112,113]. Protein–protein interactions, as
well as long-range communication, are proposed to modulate
the activities of ODC and AdoMetDC within the bifunctional
complex [111], although each decarboxylase active site in the
respective domains is able to function independently of the other
[112]. The ODC activity seems to be allosterically stimulated by
the presence of the AdoMetDC domain [114] and conversely
AdoMetDC activity is inhibited by the presence of the ODC
domain [112]. In this manner, it seems that the production of
equimolar levels of putrescine and dcAdoMet is achieved.
The potential of AdoMetDC/ODC as an antimalarial target is
largelybasedontheefﬁcacyofDFMOtopreventmalariaparasite
proliferation in vitro [115]. However, DFMO does not appear to
be as therapeutically useful as against African trypanosomiasis,
becauseitisnotcurativeofPlasmodiumbergheiinfectionsinvivo
[116]. Despite the therapeutic failure of DFMO against malaria
infections, the dependency of the parasite on polyamines for
survival has been well established [108,117–119].
New generation ODC inhibitors including APA are far more
effective than DFMO against P. falciparum and exhibit an IC50
value of ∼1 μM(Table1).However,theeffectsoftheseinhibitors
are also reversed by putrescine [108]. The apparent recovery
of parasites treated with ODC inhibitors is troublesome since
it implies that the parasite can overcome ODC inhibition through,
for example, efﬁcient polyamine uptake mechanisms (see below),
and that additional activities in the biosynthesis or uptake of
polyamines may need to be targeted.
Inhibition of AdoMetDC activity of the bifunctional protein
withMDL73811(1000-foldmoreactivethanDFMO)alsoarrests
P. falciparum growth in vitro [120], but is not curative in in vivo
malaria models (Table 1). In contrast with the trypanosomes
[37,42], inhibition of AdoMetDC activity in P. falciparum does
not result in accumulation of AdoMet levels and the methylation
status of the parasite is unaffected [117].
Co-inhibitionofbothactivitiesofplasmodialAdoMetDC/ODC
results in an additive growth-inhibitory effect and a total
block in polyamine biosynthesis, indicating possible applications
for therapeutic interventions [117]. The decarboxylase active
sites of plasmodial AdoMetDC/ODC are structurally conserved
compared with the mammalian orthologues, but the bifunctional
nature of AdoMetDC/ODC makes it attractive to target protein–
protein interacting sites instead, a strategy that is gaining
popularity for selective inhibition of multi-subunit proteins
[121,122].
A structural description of the complete AdoMetDC/ODC
bifunctional complex is lacking, mostly due to the refractory
expression of this large protein complex in heterologous
systems. However, homology models have been described for
the individual AdoMetDC and ODC domains and were used
to predict interaction sites between these domains (Figure 5)
[113,123]. The P. falciparum AdoMetDC is predicted to fall
within its own structural class [35] due to its presence within the
bifunctional protein complex (Figure 5). The homology model
of ODC showed a similar topology to those of other ODCs, but
also identiﬁed important differences in the residues involved in
its active site. These differences may be exploited for selective
inhibitor design [113,123]. Moreover, the ODC domain is more
refractory to change and is dependent on the presence of the
so-called linker or hinge region (Figure 5) of the bifunctional
complex for activity [111,114].
Inhibition of SpdS in P. falciparum
Investigations of the potential of SpdS as a drug target have not
been as extensive as for AdoMetDC/ODC, but global analyses
of the functional consequence of its inhibition suggest that
it is an important ﬂux-controlling point within the polyamine
biosynthetic pathway [119]. Treatment with the SpdS inhibitors
CHA, 4MCHA and dicyclohexylamine (Table 1) resulted in a
marked reduction in P. falciparum cell growth in vitro [109].
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Figure 5 The unique bifunctional AdoMetDC/ODC of malaria parasites
(A) AdoMetDC (N-terminus) is associated via a hinge region to the C-terminal ODC domain. Two of these ∼170kDa AdoMetDC/ODC polypeptides associate to form the functional ∼330kDa
AdoMetDC/ODC complex. aa, amino acid. (B) Predicted structural description of the bifunctional arrangement of AdoMetDC/ODC (middle panel) [143]. An ODC monomer (grey ribbon diagram in
theright-handpanel)associateswithanotherODCmonomerinahead-to-tailfashiontoformthetwosharedactivesitesoftheobligateODCdimer(right-handpanel).Tothis,theareasthatwouldbe
occupied by two AdoMetDC domainsare presented as spheres indicating preferred centre of mass of AdoMetDC docked to ODC. Each individual AdoMetDC doma i ni sf o r m e db yα-a n dβ-subunits
depicted in pink and yellow respectively in the ribbon diagram (left-hand panel).
Crystal structures of P. falciparum SpdS containing MTA
(5
 -methylthioadenosine), spermidine, spermine, AdoDATO,
dcAdoMetor4MCHAhavebeenobtained[124].Thesestructures
explained,amongotherphenomena,theactive-sitepromiscuityin
terms of spermidine binding, enabling the enzyme to synthesize
spermine [124,125]. Moreover, these structures have been used in
the further development of novel and potent inhibitors of SpdS,
identifying several active-site binders with the use of structure-
based virtual screening [126]. Clearly, the essential nature of
SpdS to the survival of P. falciparum parasites warrants further
investigation into the design of new inhibitors.
Inhibition of polyamine function in P. falciparum with polyamine
analogues
The treatment of murine malaria (P. berghei) with a combi-
nation of DFMO and the N,N
 -bis(benzyl)polyamine analogue
MDL27695 is curative of the disease. Additionally, these cured
mice were resistant to re-infection with the same parasite strain
[127]. MDL27695 rapidly inhibits growth of both chloroquine-
sensitive and -resistant P. falciparum strains in vitro (Table 1)
[127]. A combination of MDL27695 and chloroquine proved to
cause an additive effect [128]. This therefore provides evidence
of the therapeutic potential of polyamine analogues in perturbing
P. falciparum growth.
Severalofaseriesof1,3,5-triazine-substitutedpolyamineshave
shown growth-inhibitory activity against P. falciparum in the
low micromolar range, especially against chloroquine-resistant
parasites[129].Chemicallibraryscreeningofdiaminederivatives
identiﬁed compounds with some activity against plasmodia with
IC50 valuesaslowas0.7 μM,providedthesederivativescontained
a benzyloxy group [130]. There was no indication of selectivity,
but antiparasitic activity was conﬁrmed in Leishmania.
Polyamine-related metabolic pathways as drug targets
in P. falciparum
Ornithine, a substrate of ODC, seems to be homoeostatically
controlled in P. falciparum. Inhibition of the ODC activity
of AdoMetDC/ODC increases production of OAT (ornithine
aminotransferase) to catabolize potentially toxic ornithine to
glutamate-5
 -semialdehyde and ultimately to proline [117]. The
three-dimensional structure of P. falciparum OAT was recently
solved and it was shown that, even though the overall structure
is similar to that of the human protein, there are parasite-
speciﬁc differences that can be exploited for chemotherapeutic
intervention. Speciﬁcally, two cysteine residues within the loop
involved in substrate binding were found only in the parasite
OAT, and were predicted to mediate a unique interaction with
thioredoxin [131]. Thioredoxin plays a crucial role in redox
regulation in P. falciparum.
The control of ornithine levels links polyamine metabolism
to redox control in the parasite. Although there is no evidence
for the existence of trypanothione in P. falciparum, a clear
relationship between polyamine metabolism and the redox
status of the parasites is implied since the transcript levels
of 1-Cys peroxiredoxin, thioredoxin, glutathione transferase
and glutathione reductase are decreased in polyamine-depleted
parasites [117].
In the absence of polyamines, P. falciparum produces an
inducible LDC1 (lysine decarboxylase 1), which is able to form
cadaverine from lysine [117,119,132]. In addition, it seems as if
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P. falciparum possesses an LDC2 paralogue that is constitutively
expressed in the cytosol [133]. Although aminopropylcadaverine
is detectable in the parasite, the functions of the LDCs in
P. falciparum remain unclear.
Polyamine transport as a drug target in P. falciparum
Putrescine transport has been characterized in rhesus monkey
erythrocytes infected with P. knowlesi and was shown to be
dependent on temperature and competed for by spermidine and
spermine [134]. P. falciparum-infected erythrocytes exhibited
similar putrescine uptake characteristics as did P. knowlesi-
infected erythrocytes [135].
Both putrescine and spermidine are taken up across the plasma
membraneofisolatedviableP.falciparumparasitesviaasaturable
temperature-dependent process that showed competition between
differentpolyamines,aswellasthepolyamineprecursorornithine
and other basic amino acids (J. Niemand, unpublished work).
Inhibition of polyamine biosynthesis in the isolated parasites
led to increased total uptake of both putrescine and spermidine
and the rate of uptake was independent of extracellular Na
+ or
K
+ concentrations, but increased with increasing extracellular
pH. Putrescine and spermidine uptake decreased with membrane
depolarization and increased with membrane hyperpolarization.
Unlike in L. major and T. cruzi, a polyamine transporter has
as yet not been identiﬁed molecularly in Plasmodium spp.
The putrescine and spermidine uptake systems may provide a
mechanism for selective delivery of antimalarials by conjugating
them to polyamines [136,137]. This approach may prove to be
effectiveinimprovingtheinhibitorycapacityoftheantimalarials,
as well as to decrease their non-speciﬁc side-effects.
CONCLUSIONS AND FUTURE PERSPECTIVES
The inhibition of polyamine biosynthesis by DFMO has
demonstrated impressive cure rates of T. b. gambiense infections,
validating this pathway as an antiparasitic drug target. However,
the poor pharmacokinetic properties of DFMO necessitate
the discovery of alternative inhibitors targeting polyamine
metabolism. The trypanosomatids as well as malaria parasites
havevariousuniquepropertiesthatcanbeexploitedinfuturedrug-
development efforts. As such, within the trypanosomatids, the
synthesis of trypanothione and particularly the bifunctional TSA
may be targeted. Targeting the polyamine uptake mechanism to
eitherblockpolyamineuptakeorexploitthistransportmechanism
to deliver cytotoxic cargo [11,136] may be highly effective
againsttheparasites.Suchanapproachmaybeparticularlyuseful
in the case of T. cruzi, being a polyamine auxotroph, with a
highly efﬁcient putrescine/cadaverine transporter. A unique and
selective tool to inhibit AdoMetDC in trypanosomatids may be to
prevent its essential interaction with prozyme. Such targeting of
protein–protein interactions has led to the development of small-
molecule inhibitors of interactions that are currently in clinical
trials in other systems [121]. The formation of the bifunctional
AdoMetDC/ODC in plasmodia may be similarly interfered with.
Furthermore, a global understanding of the importance of the
polyamines to these parasites may highlight additional activities
that can be targeted in antiparasitic strategies [138].
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